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The robustness of parametric analyses is rarely questioned or qualified. Robustness,
generally understood, means the exact and approximate p-values will lie on the same side
of alpha for any reasonable data set; and 1) any data set would qualify as reasonable and
2) robustness holds universally, for all alpha levels and approximations. For this to be
true, the approximation would need to be perfect all of the time. Any discrepancy
between the approximation and the exact p-value, for any combination of alpha level and
data set, would constitute a violation. Clearly, this is not true, and when confronted with
this reality, the “No True Scotsman” fallacy is often invoked with the declaration it must
have been a pathological data set, as if this would obviate the responsibility to select an
appropriate research method. Ideally, a method would be selected because it is optimal,
or at least appropriate, without needing special pleading, but judging by how often
approximations are used when the exact values they are trying to approximate are readily
available, current trends do not come close to this ideal. One possible explanation might
be that there is not much information available on data sets for which the approximations
fail miserably. Examples are presented in an effort to clarify the need for exact analyses.
Keywords:
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Introduction
Approximations are used rather often, in all sorts of contexts. Sometimes this is
because the exact value is not available, or because it could be made available but
only at a prohibitive cost. In no case is the approximation ever actually preferred
to the exact value it is trying to approximate, for if this indeed is the case, then the
approximation is not an approximation. Rather, it would then be calculated for its
inherent interest.
This raises the issue of whether parametric analyses are conducted because
they are of interest in their own right, or merely as approximations to exact
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analyses. Though it is conceivable that in certain limited cases there is interest in
a parametric analysis, it is clear, when one considers the pre-testing that generally
occurs to ensure that the conditions are met to ensure the integrity of the
approximation, that the parametric analyses are, in general, just approximations,
nothing more. For example, if one were to test the data for normality by any
method, even an informal one such as appeal to the fact that we have always just
assumed normality, prior to conducting a t-test, then this undermines the notion
that the t-test is conducted for inherent interest. There is interest only
conditionally on the finding that the data are normal enough to merit such interest.
Along these lines, Bradley (1968) noted that “A corresponding parametric test is
valid only to the extent that it results in the same statistical decision [as the exact
test]” (p. 85).
We must distinguish two cases here. In one case, the choice is to
approximate or not to approximate; but if one does, then one cannot know how
well the approximation performed since the exact value cannot be computed. In
the other case, the exact value is readily available, so here the choice is to use it or
the approximation. Berger (2000) pointed out the folly, in this case, of ever using
the approximation. After all, how compelling is a test of normality in allowing for
the use of an approximation when one can instead simply compare the two values
to see how close they actually are (as opposed to how close they should tend to be
on average)? But for that matter, given that one already has the exact value, why
even consider replacing it with the approximation?
The lapse in logic that would allow a researcher to use an approximation
when the very quantity it is trying to approximate is readily available is staggering,
and yet this exact situation plays out in a huge number of randomized clinical
trials, Bradley’s aforementioned sage wisdom notwithstanding. The
randomization itself allows for exact comparisons of the treatment groups by way
of permutation tests (see, e.g., Fisher, 1935; Rigdon & Hudgens, 2015; Lu, Ding,
& Dasgupta, 2015), and yet it is the inexact parametric tests that are used far more
often, generally after going through the motions of justifying this choice by first
conducting a test of the assumptions that allegedly support the use of the
parametric test in question.
The only saving grace would be if it just didn’t matter. Sure, the exact
analyses are preferable, but given how robust the parametric analyses are, there is
very little to gain and much to lose in terms of computing time. This argument
may have been compelling decades ago, when it actually would have been
difficult to conduct a permutation test, but today this is no longer the case. It is
just as easy to do it right as it is to do it wrong. So this leaves us at the other
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aspect of this argument, it just doesn’t matter (and all the variations of this theme,
including the assertion that there are more important issues for statisticians to
concern themselves with, as if the choice of an appropriate analysis is somehow
beneath the dignity of the very party charged with doing so). Moreover, even if it
did not matter (at least numerically), that still would not provide a compelling
argument in favor of a theoretically unsound analysis.
This much is clear, and should already suffice to eradicate parametric
analyses from actual clinical trials, at least when comparing treatments. Sadly, it
has not, and the widespread delinquency of researchers who simply cannot be
bothered to concern themselves with the relative merits of various analyses is
matched by a commensurate delinquency on the part of those authorities who
could impose the need for rigor, yet somehow choose not to. And they do this
while assuring patients and funding bodies that only the best research methods
will be used. But at least we can fall back on robustness.
Everybody knows that parametric analyses are robust, but how many can
actually provide a precise formulation of what that means, operationally? How
good is good enough? What does “good enough” even mean in this case? What
does convergence as the sample size increases without bound say about the
discrepancy for this particular data set with its very finite sample size? These are
uncomfortable questions for those who continue to embrace robustness as a
justification for using approximations when in fact the exact values should be
used instead. One theorem that would be useful in supporting this case would be
along the lines of |p1 – p2 | < k/n, where k is some universal constant, n is the
sample size, and k/n bounds the absolute difference between the two p-values.
Even if this statement were true, it would still be hard to see how that would
justify the substitution of the one for the other. After all, enlightened researchers
recognize that each party may apply his or her own personal alpha level to the
results of any clinical trial (Berger, 2004). This being the case, how much error is
acceptable when, with a different choice, we can attain the ideal of no error at all?
Moreover, is such a bound of the discrepancy even true? The remainder of this
paper will illustrate that in fact it is not true for any reasonable value of k. We will
consider the chi-square approximation to Fisher’s exact test, the Smirnov test
(both exact and approximate), and the t-test in the sections to follow.

Examples of the Chi-Square Test Failing
When dealing with a single 2 × 2 contingency table, the two most common tests
seem to be Fisher’s exact test and the chi-square test. Of course, the chi-square
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test is used in other situations as well, and sometimes the exact test to which it is
compared is not Fisher’s exact test, and in some cases this test may not even have
a name (but is easily defined in terms of a test statistic and a permutation mode of
inference). Table 1 presents six data sets for which the chi-square p-value differs
markedly from its exact counterpart. In Example C1, the comparison was the chisquare test to Fisher’s exact test. Little (1989) pointed out that each expected cell
count was over five, so the usual rule of thumb would have led one to use the chisquare test and find significance at the 0.05 level (note that the p-values in the
table are one-sided, so Fisher’s exact test is not significant).
Table 1. Data sets for which the chi-square test fails badly
N
C1.
C2.
C3.
C4.
C5.
C6.

References
Little (1989)
Zelterman et al. (1995)
Cytel Software (1995, p. 11)
Cytel Software (1995, p. 17)
Berger and Lachenbruch (1998)
Hewett et al. (1999); Clancy (2000)

Data Set*
{(170,2);(162,9)}

p-values**
0.0299, 0.0162
0.0424, 0.119
0.0013, 0.1342
0.243, 0.0786
0.063, 0.047
NS***, 0.02

{(3,1);(1,3)}
{(20,230);(35,225)}
{(10,453);(2,364)}

Note: Citations abbreviated for space; see Reference section below for full reference
* Data set provided only for a single 2 × 2 contingency table
** Exact p-value first, then chi-square p-value
*** Actual p-value not reported, nor is the full data set available

Table 2. Data from StatXact (Cytel Software, 1995)
0
1
0

7
1
8

0
1
0

0
1
0

0
1
0

0
1
0

0
1
0

1
0
0

1
0
0

Example C2 is from Table 1 of Zelterman, Chan, and Mielke (1995), which
is hypothetical data in the form of two stratified 2 × 2 contingency tables. These
were {(1, 0); (3, 9)} and {(0, 0); (9, 5)}. Not only do the p-values differ
dramatically (the exact p-value is 0.0424 and the approximate chi-square p-value
is 0.119), but in fact it is the exact one that is lower. This example flies in the face
of the conventional wisdom that states that permutation tests are always
conservative so therefore exact p-values are always larger than their approximate
counterparts. Zelterman et al. (1995) note “The lesson we learn ... is that the
behavior of test statistics, such as Pearson’s chi-square, may or may not agree
with their asymptotic approximations. The only certain methods for accurate
analysis of tables with small counts is to perform exact methods based on the
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likelihood function” (p. 358) Example C3 is based on a sparse 3 × 9 contingency
table presented in the StatXact manual (Cytel Software, 1995, p. 11), which is
reproduced in Table 2.
Pearson’s chi-square test of an interaction between rows and columns has a
test statistic value of 22.29 with (3 – 1)(9 – 1) = 16 degrees of freedom, for a pvalue of 0.1342. Using the same test statistic, specifically the chi-square test
statistic, but using its exact distribution instead of the distributional assumption
results in an exact p-value of 0.0013. As in Example C2, not only are the p-values
(and the interpretations one would arrive at) grossly different from each other, but
in fact it is the exact one that would demonstrate a true treatment effect (assuming
that rows are treatments), whereas the approximate one would miss it. The
StatXact manual notes “the need to compute the exact p-value, rather than relying
on asymptotic results, whenever the data set is small, sparse, unbalanced, or
heavily tied. The trouble is that it is difficult to identify, a priori, that a given data
set suffers from these obstacles to asymptotic inference” (Cytel Software, 1995, p.
11).
Example C4 is also from the StatXact manual (Cytel Software, 1995, p. 17),
and is Fisher’s famous original tea-tasting experiment which led to the
development of Fisher’s exact test. As is well known, the experiment involved
testing the claim of a British woman that she was able to distinguish between the
two possible orders, milk first and then tea, or tea first and then milk, being
poured into a cup. This woman was presented with eight cups of tea, in which
four were of each order (and she was told this key fact). The order in which the
cups were given to her was randomized. Of the four cups with milk poured first,
she guessed right three times. Likewise, of the four cups with tea poured first, she
guessed right three times. The chi-square test yields a p-value of 0.1573 two-sided
or 0.0786 one-sided. The Fisher exact p-value is 0.243, which is not even close.
Example C5 regards data presented at the December 15, 1995 FDA Blood
Products Advisory Committee meeting. Hospitalization due to a targeted
respiratory disease was required by 20/250 (8.0%) patients on a biological
treatment arm and 35/260 (13.5%) patients on the control arm. Pearson’s
uncorrected chi-square test yielded p = 0.047 two-sided, and significance was
declared at the prospectively specified 0.05 alpha level (two-sided). But the
nominal 0.05 alpha level is preserved only if the true probability of a Type-I error
is no greater than 0.05. A fair question, then, is how likely one would be to obtain
data at least as significant (p < 0.047), by using this chi-square test, assuming
nothing more than random allocation of patients to treatment groups. The answer,
p = 0.063, is provided by Fisher’s exact test, which of course does not attain
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statistical significance at the 0.05 alpha level. The StatXact manual points out that
“The term ‘asymptotically’ means ‘given a sufficient sample size’, though it is not
easy to describe the sample size needed for the chi-square distribution to
approximate well the exact distribution of the Pearson statistic” (Cytel Software,
1995, p. 12).
Example C6 is based on Clancy’s (2000) letter to the editor regarding
Hewett, Lindenfeld, Riccobene, and Noyes’ (1999) paper, in which the authors
evaluated the effect of neuromuscular training on the incidence of knee injury in
female athletes. There were ten injuries among 463 untrained athletes and two
injuries among 366 trained athletes. The chi-square test was reported to yield
p = 0.02. Clancy reported a non-significant p-value with Fisher’s exact test, and
also pointed out that one cell had both an actual and an expected cell count under
five, so that Fisher’s exact test would be the more reliable of the two, in keeping
with conventional wisdom. Notably, Hewett, Levy, and Noyes (2000) responded
to the letter by resorting to appeal to credentials, stating essentially that they used
an “excellent” statistician, so therefore whatever he came up with must be correct
by virtue of his coming up with it. A second “unbiased” statistician confirmed this.
Even in the absence of a reason for suspicion, suspicion must still arise
when an argument is defended by appeal to credentials. This is, after all,
tantamount to an admission that there is no better defense for the argument than
credentials. One has to wonder just how “unbiased” the second statistician truly
was, and also how many competent statisticians (with the fortitude to refuse to
sign off on an analysis so poorly planned) were also contacted. Competent
statisticians know to use Fisher’s exact test when the expected cell counts, or any
one of them, is less than five; even better statisticians would recognize the
irrelevance of the expected cell counts and instead use Fisher’s exact test any time
it differs substantially from the chi-square test. And still better statisticians would
recognize that they are not in a position to determine how close an approximation
needs to be in order that it be preferred to the quantity it is trying to approximate,
so they would simply use Fisher’s exact test routinely.

Examples of the Approximate Smirnov Test Failing
When dealing with a single ordered 2 × J table, the best test that is offered as a
routine option (no programming required) in commercially available software
packages is the exact Smirnov test, a standard feature of StatXact. See Section
10.1 of Hollander and Wolfe (1973) and Section 1.6 of Lehmann (1975). Note
that while it is customary to speak of the Smirnov test as a two-sided approximate
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test, we use this term to denote the exact one-sided version. Essentially, the only
difference between the one-sided and the two-sided version is the absence or
presence, respectively, of absolute values around the directed difference of CDFs
to be maximized. Whether one-sided or two-sided, the approximate test that bears
the same name often gives strikingly different p-values from the exact version for
the same data set, as we will demonstrate in Table 3. Note that the exact Smirnov
test p-values (but not the approximate ones) for these data sets appeared in Table
2 of Berger (2002), and some of them seem to contradict what we are presenting
now in our Table 3. The reason for this is the newfound ability of StatXact to
compute exact Smirnov p-values immediately for such large data sets, whereas
only a few years ago only Monte Carlo approximations were feasible.
Table 3. Ordered 2 × J tables for which the approximate Smirnov test fails badly
N
S1.
S2.
S3.
S4.
S5.
S6.
S7.
S8.
S9.

References
Fentiman et al. (1983)
Fox et al. (1993)
Fox et al. (1993)
Elwood (1998)
TOAST (1998)
Clark et al. (1999)
Clark et al. (1999)
Shelton et al. (2001)
Staszewski et al. (2001)

Data Set
{(6,8,4,2,3);(3,2,8,0,10)}
{(1,5,16);(0,0,22)}
{(12,3,7);(3,7,12)}
{(33,5,545);(29,8,836)}
{(291,168,176);(270,161,215)}
{(207,19,80);(181,25,101)}
{(187,15,104);(169,32,106)}
{(83,14,5);(72,12,14)}
{(149,29,104);(144,15,121)}

p-values*
0.0138, 0.0296
0.0106, 0.1947
0.0108, 0.0252
0.0258, 0.6823
0.0379, 0.1376
0.0209, 0.0988
0.0938, 0.3242
0.0766, 0.4147
0.1051, 0.3238

Note: Citations abbreviated for space; see Reference section below for full reference
* Exact one-sided Smirnov p-value first, then the approximate one-sided Smirnov p-value

Notice that in each case the approximate p-value is much larger than its
exact counterpart. This refutes the common misunderstanding that exact p-values
are always overly-conservative and therefore larger than the approximate p-values
they would (and should) replace. Example S1 comes from a study of talc for
malignant pleural effusions. There were 46 patients, and 23 were randomized to
each group: talc and mustine. Some patients were considered to be “not assessable”
because they died within a month of pleurodesis. Among the other patients (who
were assessed), success or failure was defined in terms of radiologic criteria of
effusion control. In addition to this binary success endpoint, patients were also
classified as being alive or dead at the time the article was written, and as having
had or not had evidence of recurrent effusion. So all in all we have four binary
endpoints:
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1.
2.
3.
4.

Died prior to assessment or not;
Dead or alive at the end of the study;
Success or not;
Recurrence or not.

This would appear to give 2 × 2 × 2 × 2 = 16 outcomes, but in fact the first
two binary endpoints are fusible, because being alive at the end of the study
necessarily entails also being alive long enough to be assessed. So instead of
2 × 2 = 4 outcomes for the first two binary endpoints above, we recognize the
structural zero (one cannot die prior to being assessed and also be alive at the end
of the study), and remove it to create a trichotomous information preserving
composite endpoint, or IPCE, (died prior to assessment, assessed but dead at
study end, alive at study end). See Berger (2002) for more information on the
construction of the IPCE. We also note that the two binary endpoints success
(yes/no) and recurrence (yes/no) are fusible, because recurrence is possible only if
success was achieved in the first place, so we again have a structural zero (one
cannot recur without having succeeded in the first place). Removing it gives the
IPCE (no success, success then recurrence, success without recurrence). We have
gone from 2 × 2 × 2 × 2 = 16 possible outcomes to only 3 × 3 = 9. But in fact
further savings is possible too, as becomes evident from inspection of Table 4.
Dying before assessment precludes the possibility of a success, so the two
lower left cells, labeled “SZ” in Table 4, are structural zeros. We make the
simplifying assumption that death supersedes recurrence, and so we equate the
two cells labeled “3" in Table 4. The upper right cell labeled “RZ” was a random
zero; that is, there could have been patients surviving without success, but as it
turned out, none did. This leaves only five active outcomes, labeled 1-5 in Table
4:
1.
2.
3.
4.
5.

Died prior to being assessed;
Died after being assessed but without success;
Died after success;
Alive at study end but recurred;
Alive at study end without recurrence.

These outcomes are, of course, in order of increasing clinical benefit, and the data,
as presented in Table 3, were (6, 8, 4, 2, 3) in the mustine group and
(3, 2, 8, 0, 10) in the talc group, and the one-sided (to show a benefit of talc in
shifting to more favorable outcomes) Smirnov p-values were 0.0138 (exact) and
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0.02955 (approximate). If one were to use the two-sided 0.05 alpha level and then
cut it in half for a 0.025 one-sided alpha level (which seems to be lacking in any
real basis, yet is still used quite often as a policy), then only the exact Smirnov
test would show a statistically significant improvement in outcomes associated
with talc.
Table 4. The construction of the IPCE for example S1

No Success
Success, then Recurrence
Success, no Recurrence

Died Before
Assessment
1
SZ
SZ

Assessed,
then Died
2
3
3

Alive at
Study End
RZ
4
5

Examples S2 and S3 both represent the same patients, with the same
endpoint, with the same treatments. All that varies is the timing of the
measurement. Specifically, Example S2 is Day 2 and Example S3 is Days 1-5,
and both come from a study of combination therapy for nausea (Fox, Einhorn,
Cox, Powell, & Abdy, 1993). What is so amazing is the complete reversal in the
direction of the shift. The endpoint we consider is response, which is scored as
complete, major, or none. Note that this endpoint is the IPCE of two component
binary response endpoints presented by Fox et al., specifically the response rate
and the complete response rate. Clearly, the two endpoints are fusible, since a
complete response implies also a response.
At Day 2, the data were (1, 5, 16) in the ondansetron group and (0, 0, 22) in
the combination (ondansetron plus dexamethasone plus chlorpromazine) group. In
other words, there was absolutely no effect of the combination therapy for the
response rate (22/22 vs. 21/22), but a fairly strong effect on the complete response
rate (22/22 vs. 16/22). At the Days 1-5 assessment, the situation was reversed,
with (12, 3, 7) in the ondansetron group and (3, 7, 12) in the combination group.
Now there was not much of an effect of the combination therapy for the complete
response rate (12/22 vs. 7/22), but a fairly strong effect on the overall response
rate (19/22 vs. 10/22). Either binary endpoint would show significance at the 5%
alpha level at one time point but not at the other, with one-sided Fisher’s exact
test p-values of 0.5000 for the Day 2 overall response rate, 0.0106 for the Day 2
complete response rate, 0.0049 for the Days 1-5 overall response rate, and 0.1116
for the Days 1-5 complete response rate. The exact Smirnov test yields one-sided
p-values of 0.0106 (Day 2) and 0.0108 (Days 1-5). The approximate test yields
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one-sided p-values of 0.1947 and 0.02518. Once again, only the exact Smirnov
test shows statistical significance at the customary 0.025 one-sided level of
significance.
Example S4 is reinfarction data, in which the reinfarction could be
confirmed or not, or there could be no reinfarction at all. Each patient can be
scored on an ordered categorical scale with three categories, (confirmed
reinfarction, reinfarction not confirmed, no reinfarction). Note that once again this
is the IPCE for two binary endpoints originally presented. The data for the two
treatment groups (placebo, then sotalol) are presented in Table 3, and the Smirnov
test was used to compare the groups. As can be seen, the asymptotic version of
the test was way off, to the point of being almost unbelievable, relative to the
exact Smirnov test. The exact and approximate one-sided p-values were 0.0258
and 0.6823. Note that a one-sided p-value is not, in general, half the
corresponding two-sided p-value, and also that a one-sided p-value can exceed 0.5
if the trend is in the “wrong” direction. Of course, that is not the case with the
data at hand, as we tested for the direction of sotalol being superior, and the data
do trend in this direction. So it is unclear why the asymptotic test would behave
this way. One must ask if the data themselves might suggest the need for the exact
version of the test. Berger (2000) reports that “It is unclear how one would
determine the advisability of the approximate test, but if one were to ‘think
unconditionally’ then the small middle margin would not be a concern. The large
sample sizes (over 500 per group), coupled with expected cell counts that all
exceed five, would certainly be reassuring” (p. 1322).
Example S5 concerns danaparoid for acute ischemic stroke. The TOAST
Investigators (The Publications Committee for the Trial of ORG 10172 in Acute
Stroke Treatment Investigators [TOAST], 1998) presented two binary endpoints,
favorable outcomes (yes or no) and very favorable outcomes (yes or no), but
again these two binary endpoints are clearly fusible, since a very favorable
outcome implies also a favorable outcome. The IPCE is an ordered categorical
outcome variable with categories for (unfavorable, favorable, very favorable). The
TOAST Investigators inexplicably and indefensibly excluded some randomized
patients from the analysis they called “intent-to-treat”, but of course the correct
intent-to-treat analysis would include all patients randomized. For now, we note
that this set of patients can be classified by favorable outcomes at Day 7 as
(291, 168, 176) in the placebo arm and (270, 161, 215) in the danaparoid group.
The one-sided Smirnov p-values are 0.0379 (exact) and 0.1376 (approximate).
Examples S6 and S7 both come from the study of Clark et al. (1999)
comparing rt-PA to placebo for ischemic stroke. The primary endpoint was a
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complete recovery, defined as an NIHSS score of 0 or 1, at Day 90. A second
binary endpoint was clinical improvement, defined as either a complete recovery
(inexplicably now defined as an NIHSS score of 0, in contrast to the earlier
definition which included also an NIHSS score of 1) or a change from baseline of
at least 11 points. If we ignore the inconsistency in how “complete recovery” is
defined (first as an NIHSS score of 0 or 1, then as just 0), then clearly a complete
recovery implies a clinical improvement, so the two endpoints are fusible, and we
really have a single trichotomous endpoint, (no improvement, clinical
improvement, complete recovery), where “no improvement” is short hand for
either no improvement or improvement not reaching the threshold for clinical
improvement. With this endpoint, the data appear to be (we cannot be sure, since
only proportions, and not actual patient counts, were presented in the original
report) (207, 19, 80) at Day 30 for the placebo arm and (181, 25, 101) at Day 30
for the rt-PA arm. The one-sided Smirnov test yields p-values of 0.02094 (exact)
and 0.09884 (approximate). At Day 90 the data were (187, 15, 104) in the placebo
group and (169, 32, 106) in the rt-PA group, with corresponding one-sided pvalues of 0.0938 (exact) and 0.3242 (approximate).
Example S8 comes from a study of St. John’s wort for major depression.
Shelton et al. (2001) measured depression with two binary endpoints, specifically
remission and response. Remission is defined as HAM-D ≤ 7 and CGI-I 1 or 2,
whereas response is defined as HAM-D ≤ 12 and CGI-I 1 or 2. Clearly these two
endpoints are fusible, because a remission implies a response, so the IPCE would
be (no response, response without remission, remission), and the data were
(83, 14, 5) in the placebo group (n = 102) and (72, 12, 14) in the St. John’s wort
group (n = 98). The Smirnov p-values were 0.0766 (exact) and 0.4147
(approximate).
Example S9 comes from a study of combination therapy in adults with HIV.
Staszewski et al. (2001) presented two binary outcomes, HIV RNA levels of 50
copies per mL or less and HIV RNA levels of 400 copies per mL or less.
Obviously, the former implies the latter, so we again have a trichotomous IPCE of
fusible endpoints, copies (> 400, 50-400, < 50). What was called the intent-totreat population was certainly not that, as it excluded 35 of the 562 patients
randomized. The true data set, as best as it can be reconstructed from the
incomplete presentation published, is (149, 29, 104) in the abacavir arm and
(144, 15, 121) in the indinavir arm, each in the presence of lamivudine and
zidovudine (hence combination therapy). The Smirnov p-values were 0.1051
(exact) and 0.3238 (approximate).
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Several recurrent themes emerge from the examples in this section. First,
and most obvious, notice that the exact Smirnov test always provides a lower pvalue than the approximate Smirnov test does, and notice also that in most cases,
the approximate one is not even close. It seems reasonable, then, to suggest that
the approximate Smirnov test never be used in practice, even if other
approximations are accepted.

Examples of the t-Test Failing
The t-test is often used for continuous outcomes when the variance is not known.
It is somewhat ironic that, while we are up front about not knowing the variance,
we still wish to cling to this notion that we can somehow know that the data are
normally distributed, despite Geary (1947) stating clearly that no data are
normally distributed. Table 5 presents four examples in which the t-test gave
results that differed markedly from corresponding exact results.

Table 5. Data sets for which the t-test fails badly
N
T1.
T2.
T3.
T4.

References
Williams et al. (2000); Barber and Thompson (2000)
Chaudhry et al. (2002); Jacobs (2003)
Chaudhry et al. (2002); Jacobs (2003)
Chaudhry et al. (2002); Jacobs (2003)

p-values*
0.01, 0.79
0.054, 0.004
0.21, 0.016
0.054, 0.006

Note: Citations abbreviated for space; see Reference section below for full reference

Example T1 bears some similarity to Example C6, in that one set of authors
argued that an approximate test should be used after it was already established
that an exact method was needed. In this case, the context was open access
follow-up for inflammatory bowel disease, and its effect on costs. One particular
endpoint was secondary care costs. Williams et al. (2000) correctly pointed out
that:
“Because data on use of resources tend to be highly skewed, routine
parametric statistics are not appropriate. We therefore assessed
significance by the Mann-Whitney U-test.” (p. 545)
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Using this proper analysis, the between-group p-value for secondary care costs is
presented in Table 4 of the original article as 0.01, based on a mean cost of 582
(SD = 808) in the open access arm and 611 (SD = 475) in the routine care arm
(the units are not provided in the table). Barber and Thompson (2000) argued that
the means are most relevant, and:
“[T]he most appropriate simple method for comparing mean costs is
the ordinary t-test. By using the means and standard deviations in each
group reported by the authors, we have calculated p-values from ttests ... one of the authors’ main conclusions – that open access followup used fewer resources in secondary care – is not supported: The pvalue from the t-test is 0.79.” (p. 1730)
Berger (2002) noted that there are two issues here, specifically the choice of
test statistic (difference of means, difference of mean ranks, difference of Van der
Waerden normal scores, or something entirely different) and the mode of
generating a reference distribution. Differences in means can be accompanied by
differences in shape and/or spread, so the t-test certainly is not always the most
powerful test, even to detect the difference in means. But aside from this, even if
we were to decide upon the difference of means as the test statistic, this certainly
should not imply that we also use an approximation instead of an exact analysis.
One can easily conduct an exact t-test, using the difference of means as the test
statistic, and the permutation reference distribution to evaluate statistical
significance.
Examples T2-T4 all come from the same study. Specifically, Chaudhry,
Schroter, Smith, and Morris (2002) used the approximate t-test for five measures
of readers’ perceptions of papers with and without declarations of competing
interests. These measures were interest, importance, relevance, validity, and
believability, and the corresponding p-values for the five measures were 0.004,
0.016, 0.006, 0.001, and < 0.001. Jacobs (2003) re-analyzed the data with exact
methods, after pointing out the flaws in using approximate methods for the data at
hand. Three of the p-values became non-significant, specifically interest
(p = 0.054), importance (p = 0.21), and relevance (p = 0.054). Of course, 0.054 is
close to 0.05, so one might be tempted to declare it close enough. This is bad
policy, and bad statistics, and not to be confused with selecting an alpha level
other than 0.05. While it is perfectly reasonable to select an alpha level other than
0.05, maybe even 0.055, this selection needs to be made prior to viewing the data
(and the p-value). Otherwise, one is left wondering just how broad this fuzzy
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inclusion region actually is. Would 0.06 have been OK? What about 0.07? Where
is the line drawn? In other words, what is alpha? And if alpha is not what we said
it was up front, then we have a problem with the usage of alpha, and we are
drawing the bull’s eye around where the dart happened to hit.
Moreover, notice that the p-value for importance went from 0.016 to 0.21
when the analysis went from approximate to exact. This, as well as some of the
other examples in Table 1, may well surprise those who consider the choice of an
exact or an approximate test to be a “fourth decimal problem” that hardly
warrants the attention of today’s modern statistician. The StatXact manual states
that “It is wise to never report an asymptotical p-value without first checking its
accuracy against the corresponding exact or Monte Carlo p-value. One cannot
easily predict a priori when the asymptotic p-value will be sufficiently accurate”
(Cytel Software, 1995, p. 21). This is certainly excellent advice, but we can go a
step further and ask why one would then discard the gold standard, the exact
permutation p-value, once it is in hand, to use instead an approximation to it?

Summary and Conclusions
“Robustness procedures are generally considered to be statistical methods which
are insensitive to small deviations from the underlying assumptions” (Prescott,
1998, p. 3864), and often this vagueness regarding how insensitive and how small
the deviations must be allows for excessive discretion in filling in the blanks. That
is to say that many researchers operate as if this robustness is absolute, so that
there is no sensitivity at all no matter the magnitude of the deviation or how it is
quantified. In point of fact, there seems to be no reliable method for imputing an
exact p-value based on only the combination of knowledge of the approximate pvalue and appeal to this alleged robustness. The fact that an exact p-value can fall
anywhere on the unit interval even once we know the value of the approximate pvalue should serve as ample demonstration that any notion of robustness being
absolute is an illusion.
There might still be a value in computing approximate p-values anyway, if
there were some added cost or difficulty involved in computing the exact p-value.
In some applications this in fact is the case, but certainly not in all, and it is worth
the effort to determine which case we are in. If an exact p-value can be computed
relatively easily, with no prohibitive cost, then it is difficult to imagine any valid
argument for not doing so. This remains the case even if one can put forth a
compelling argument in favor of presenting an approximate p-value. For example,
it may be the case that precedent favors the approximate p-value, which has
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always been computed in the past. We want to see how the present data compare
to past data sets, and those older ones were summarized, for example, with t-tests,
and we do not have access to the complete data that would enable us to conduct
exact analyses of those older data sets. In this case, it seems reasonable to
compute the t-test on the new data set for the sake of comparing apples to apples
and oranges to oranges, but this does not preclude the possibility of also
computing an exact p-value in addition to the approximate one. Under no
circumstances should we ever pretend to know the exact p-value without actually
computing it.
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